Highlights and Quick Summary
- Debt/Equity for the quarter ending September 30, 2022 was -2.97 (a 0.6% increase compared to previous quarter)
- Year-over-year quarterly Debt/Equity decreased by -46.36%
- Annual Debt/Equity for 2021 was -5.55 (a -61.79% decrease from previous year)
- Annual Debt/Equity for 2020 was -14.51 (a -1133.36% decrease from previous year)
- Annual Debt/Equity for 2019 was 1.4 (a 111.73% increase from previous year)
Visit stockrow.com/BCRX
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Debt/Equity of BioCryst Pharmaceuticals, Inc.
Most recent Debt/Equityof BCRX including historical data for past 10 years.Interactive Chart of Debt/Equity of BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | – | -2.97 | -2.96 | -3.73 | – |
| 2021 | -5.55 | -2.11 | -2.82 | -3.86 | -5.55 |
| 2020 | -14.51 | 1.49 | 0.71 | 14.88 | -14.51 |
| 2019 | 1.4 | -1.21 | -5.42 | 2.38 | 1.4 |
| 2018 | 0.66 | 0.45 | 0.49 | 0.39 | 0.66 |
| 2017 | 0.31 | 0.26 | 1.07 | 0.66 | 0.31 |
| 2016 | 16.15 | 6.35 | 0.19 | 0.09 | 34.05 |
| 2015 | 0.05 | 0.0 | 0.0 | 0.0 | 0.05 |
| 2014 | 0.0 | 0.0 | 0.0 | -5.24 | 0.0 |
| 2013 | -26.64 | 8.8 | -3.32 | -10.56 | -26.64 |
| 2012 | -66.08 | 3.07 | 1.92 | 1.3 | -66.08 |
Business Profile of BioCryst Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology